Regional Anesthesia MorbidityNCT07698665
Ketamine Versus Dexmedetomidine as an Adjuvant in Scalp Block in Supratentorial Brain Tumor Excision Surgeries
A study testing Scalp Block with Bupivacaine in people with Regional Anesthesia Morbidity and Supratentorial Brain Tumor, run by Cairo University at 2 sites in Egypt.
Trial summary
Supratentorial brain tumor surgeries are associated with significant nociceptive stimulation and postoperative pain, which may adversely affect patient outcomes. Scalp block has emerged as an effective regional anesthetic technique to improve analgesia and reduce opioid consumption. Read more about this study
- Who is it for?
- Ages 20 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Regional Anesthesia Morbidity, Supratentorial Brain Tumor, Acute Pain
- What is being tested?
- Scalp Block with Bupivacaine
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 90 participants
- Where
- 2 sitesEgypt
- Study dates
- 1 Jan 2026to 30 Jul 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Age from 20 to 60 years, both sexes, American Society of Anesthesiologists (ASA) physical status II-III, Supratentorial tumor excision, Supine Position.
- and operation time: less than 6 hours.
Who cannot join
- Patient refusal, disturbed consciousness level (Glasgow Coma Scale [GCS] < 15). Patients who required reintubation during the study period, those not extubated. immediately after surgery, or those who awoke with neurological deficits impairing. pain assessments were excluded from the final analysis, history of psychotic disorders or previous surgeries, Poor cognitive function.
- Postictal state or uncontrolled/recurrent seizures, known allergy to dexmedetomidine or ketamine, difficult intubation (Mallampati score > III) or multiple intubation attempts, operation duration > 6 hours, renal dysfunction (creatinine > 1.2 mg/dL, BUN > 20 mg/dL), heart block and patients with chronic headache disorders or those receiving chronic analgesic therapy (for >3 months) were excluded.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt2 sites, 2 recruiting
- Recruiting
Cairo university
Cairo, Governorate, 002
Nagy Malak, 01552480258, nagymalak12345@gmail.com
Nagy Malak, 01552480258, nagymalak@kasralainy.edu.eg
- Recruiting
Cairo university Hospitals. kasralainy
Cairo
Nagy M Nashed, MD, 01552480258, nagymalak12345@gmail.com
nagymalak12345@gmail.com
About this study
Official title: Efficacy of Ketamine Versus Dexmedetomidine as an Adjuvant to Bupivacaine in Scalp Block in Adults Undergoing Supratentorial Brain Tumor Excision Surgeries for Hemodynamics and Pain Control, Double-blinded Randomized Study
Supratentorial brain tumor surgeries are associated with significant nociceptive stimulation and postoperative pain, which may adversely affect patient outcomes. Scalp block has emerged as an effective regional anesthetic technique to improve analgesia and reduce opioid consumption.
Objective: To compare efficacy of ketamine versus dexmedetomidine as adjuvants to bupivacaine in scalp blocks for supratentorial brain tumor surgeries, focusing on analgesia, opioid consumption, and hemodynamic stability.
Read more
Methods:
This randomized double-blinded controlled trial included 80 patients undergoing supratentorial tumor excision, allocated equally into two groups: Group K received bupivacaine with ketamine (2 mg/kg), and Group D received bupivacaine with dexmedetomidine (1 µg/kg). Intraoperative hemodynamics, fentanyl consumption, postoperative pain scores (NRS), analgesic requirements, and complications were assessed.
Read the detailed description
The study was designed as a prospective, double-blind, randomized controlled clinical trial to evaluate efficacy of Ketamine versus Dexmedetomidine as an adjuvant to Bupivacaine in Scalp Block in Adults undergoing Supratentorial Brain Tumor Excision Surgeries for Hemodynamic and Pain Control.
The study was carried out in neurosurgery operating rooms at Cairo University Hospital, Faculty of Medicine, Cairo University.
The study was approved by the Ethics Committee of Faculty of Medicine, Cairo University, MS-483-2025 Egypt. The trial was preregistered on clinicaltrials.gov, NCT06168903.Written informed consent was obtained from all patients. The Consolidated Standards of Reporting Trials (CONSORT) guidelines were adhered Informed written consent was obtained from each patient. There are adequate provisions to maintain participants' privacy and confidentiality of the data.
Randomization will be performed using computer-generated numbers. Allocation concealment will be maintained using serially numbered, opaque, and sealed envelopes. Investigators will remain blind to the sequence, with group assignments contained in envelopes marked only with case numbers. Before each case, a study nurse or assistant will open the corresponding numbered envelope to reveal the patient's group assignment.
- Dexmedetomidine (D):): Patients will receive a scalp block with a 20 ml syringe containing 1 mg/kg of 0.5% bupivacaine and 1 µg/kg of dexmedetomidine, with the remainder filled with saline.
- Ketamine (K): Patients will receive a scalp block with a 20 ml syringe containing 1 mg/kg of 0.5% bupivacaine and 2 mg/kg of ketamine, with the rest filled with saline. The syringes will be prepared by an anesthesia technician and handed blindly to the anesthetist to administer the block.
Study Protocol:
Patients visited the pre-anesthesia room before the procedure. All patients received explanation of Numerical Rating Scale (NRS) for pain assessment, which ranges from 0 (no pain) to 10 (most severe pain) [17].
Standard monitoring was applied, including electrocardiography (ECG), non-invasive, invasive blood pressure, and Oxygen Saturation (SaO₂), and baseline vital signs were recorded, including heart rate, systolic and diastolic blood pressure, mean arterial pressure, and oxygen saturation.
Anesthesia was induced with intravenous propofol 2 mg/kg, fentanyl 2 µg/kg, and atracurium 0.5 mg/kg, with mask ventilation for 3 minutes followed by tracheal intubation. Intraoperative signs of inadequate analgesia, such as tachycardia or hypertension exceeding 20% of baseline, were managed with additional 50 µg doses of fentanyl, and total fentanyl consumption was recorded. Anesthesia was maintained using intermittent positive pressure ventilation with isoflurane 0.8-1.2 MAC in an oxygen/air mixture, and atracurium infusion 0.5 mg/kg, while end-tidal CO₂ was monitored.
After induction, bilateral scalp blocks were performed using a 23G needle, with local anesthetic infiltrated around supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, lesser occipital, greater occipital, and great auricular nerves, 2-3 mL per nerve.
Scalp Block Techniques Supraorbital Nerve Block Patient was seated with the head slightly forward and eyes closed. The supraorbital notch was palpated, and a needle was inserted approximately 1 cm above the notch. 2 ml of local anesthetic were injected at this site.
Supratrochlear Nerve Block With the patient in the same position, the injection site was located one finger's breadth medial to the supraorbital nerve. The needle was redirected medially, and 3 mL of local anesthetic was administered.
Zygomaticotemporal Nerve Block The patient's head was turned so that the target side was facing upward. Landmarks included the orbital rim and zygomatic arch. A dual injection technique was used, with 1 mL injected deeply and 2 mL subcutaneously.
Auriculotemporal Nerve Block The injection site was 1-1.5 cm anterior to the ear, above the tragus, taking care to avoid superficial temporal artery. 3ml of local anesthetic were injected subcutaneously.
Greater Occipital Nerve Block With the head turned or the patient seated, the occipital artery was palpated, approximately 3-4 cm lateral to the external occipital protuberance. The needle was inserted perpendicular to the skin medial to the artery, and 3 mL of local anesthetic was injected subcutaneously.
Lesser Occipital Nerve Block Injection site was located about 2.5 cm lateral to the greater occipital nerve block site. 3 ml of local anesthetic were administered subcutaneously.
Great Auricular Nerve Block (Postauricular Branches) The injection site was 1.5 cm posterior to the ear at the level of the tragus. The needle was inserted perpendicular to the bone, withdrawn slightly, and 3 mL of local anesthetic was injected subcutaneously [5].
Hemodynamic Monitoring HR and BP were recorded baseline before induction, 1 and 5 minutes after induction, at intubation, 5 minutes after the scalp block, 5 minutes after pin insertion, 5minutes after skin incision, at 15min, 20min, 25min, 30min,35min, 40min,60min, 95min, 3hour, 4hour and after extubating as well as in post-anesthesia care unit (PACU) and upon arrival in surgical ICU.
Deviations from baseline were managed according to protocol:
- Bradycardia (<20% below baseline) was treated with atropine 0.04 mg/kg
- Hypotension (<20% below baseline) with ephedrine 5 mg IV
- Hypertension or tachycardia (>20% above baseline) with fentanyl 50 µg IV. At the end of surgery, residual neuromuscular blockade was reversed using atropine 0.01 mg/kg and neostigmine 0.05 mg/kg. Extubating was performed when the patient met standard criteria, including a Glasgow Coma Scale >8, adequate cough and gag reflex, sufficient motor strength, a train-of-four (TOF) ratio >0.9, ability to hold head tilt or hand grip for 5 seconds, adequate tidal volume and oxygenation and hemodynamic stability.
In PACU, standard monitoring was continued, pain was assessed using NRS. Patients were discharged when modified Aldrete Score exceeded 9 [18].
Paracetamol and ketorolac were given as rescue analgesia when NRS score was more than 4. The time from extubating to the first analgesic request was recorded, and total postoperative analgesic consumption was documented.
Any hemodynamic instability, including hypertension, tachycardia, bradycardia, or hypotension, as well as nausea, vomiting, and other complications, were recorded.
Hemodynamic monitoring (MAP in mmHg) was Pain assessment using NRS (0-10) was conducted upon PACU arrival, 2, 4, 6, 8, 12and 24 hours postop
- Being tested
- Scalp Block with Bupivacaine
- Keywords
- Scalp block, Dexemetomedine, Supratentorial
- Medical subject headings
- Acute Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Scalp Block with BupivacaineDrug
After induction, bilateral scalp blocks were performed using a 23G needle, with local anesthetic infiltrated around supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, lesser occipital, greater occipital, and great auricular nerves, 2-3 mL per nerve.
| Study group | Role | What they receive |
|---|---|---|
| Dexmedetomidine (D) | Experimental | Patients will receive a scalp block with a 20 ml syringe containing 1 mg/kg of 0.5% bupivacaine and 1 µg/kg of dexmedetomidine, with the remainder filled with saline. Receives: Drug: Scalp Block with Bupivacaine |
| Ketamine (K): | Active comparator | Patients will receive a scalp block with a 20 ml syringe containing 1 mg/kg of 0.5% bupivacaine and 2 mg/kg of ketamine, with the rest filled with saline. The syringes will be prepared by an anesthesia technician and handed blindly to the anesthetist to administer the block. Receives: Drug: Scalp Block with Bupivacaine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Analgesic efficacy of dexmedetomidine versus ketamine as adjuvants in scalp blocks
Compare analgesic efficacy of dexmedetomidine versus ketamine as adjuvants in scalp blocks for supratentorial tumor resection by measuring total intraoperative fentanyl consumption (in µg).
Measured: 6 hours
Secondary outcomes (6)
Compare the time duration after extubating to request the first analgesia.
Compare the time duration after extubating to request the first analgesia.
Measured: 24 hours
Total analgesic consumption.
Total analgesic consumption in intraoperative and postoperative period till 24 hours.
Measured: 24 hours
NRS pain score
NRS pain score at various time points in the postoperative period till 24 hours.
Measured: 24 hours
Nausea and vomiting
Nausea and vomiting incidence
Measured: 24 hours
Side effects
Systemic side effects of ketamine (sedation, hallucinations, nystagmus).
Measured: 24 hours
Side effects
Systemic side effects of dexmedetomidine (bradycardia).
Measured: 24 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jul 2026
- Study start1 Jan 2026
- Primary completion30 Jul 2026 (estimated)
- Study completion30 Jul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Regional Anesthesia MorbidityStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 90 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Nagy Malak , MD, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07698665
- Sponsor's protocol ID
- MS-483-2025
- Status last verified
- Jul 2026
- First submitted
- 7 Jul 2026
- Last updated
- 13 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 13 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of Ketamine Versus Dexmedetomidine as an Adjuvant to Bupivacaine in Scalp Block in Adults Undergoing Supratentorial Brain Tumor Excision Surgeries for Hemodynamics and Pain Control, Double-blinded Randomized Study
- ClinicalTrials.gov ID
- NCT07698665
- Acronym / sponsor ID
- MS-483-2025
- Keywords
- Scalp block, Dexemetomedine, Supratentorial
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 90 participants (estimated)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- 1 Jan 2026 (actual)
- Primary completion
- 30 Jul 2026 (estimated)
- Study completion
- 30 Jul 2026 (estimated)
- First posted
- 13 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Supratentorial brain tumor surgeries are associated with significant nociceptive stimulation and postoperative pain, which may adversely affect patient outcomes. Scalp block has emerged as an effective regional anesthetic technique to improve analgesia and reduce opioid consumption.
Objective: To compare efficacy of ketamine versus dexmedetomidine as adjuvants to bupivacaine in scalp blocks for supratentorial brain tumor surgeries, focusing on analgesia, opioid consumption, and hemodynamic stability.
Methods:
This randomized double-blinded controlled trial included 80 patients undergoing supratentorial tumor excision, allocated equally into two groups: Group K received bupivacaine with ketamine (2 mg/kg), and Group D received bupivacaine with dexmedetomidine (1 µg/kg). Intraoperative hemodynamics, fentanyl consumption, postoperative pain scores (NRS), analgesic requirements, and complications were assessed.
Detailed description
The study was designed as a prospective, double-blind, randomized controlled clinical trial to evaluate efficacy of Ketamine versus Dexmedetomidine as an adjuvant to Bupivacaine in Scalp Block in Adults undergoing Supratentorial Brain Tumor Excision Surgeries for Hemodynamic and Pain Control.
The study was carried out in neurosurgery operating rooms at Cairo University Hospital, Faculty of Medicine, Cairo University.
The study was approved by the Ethics Committee of Faculty of Medicine, Cairo University, MS-483-2025 Egypt. The trial was preregistered on clinicaltrials.gov, NCT06168903.Written informed consent was obtained from all patients. The Consolidated Standards of Reporting Trials (CONSORT) guidelines were adhered Informed written consent was obtained from each patient. There are adequate provisions to maintain participants' privacy and confidentiality of the data.
Randomization will be performed using computer-generated numbers. Allocation concealment will be maintained using serially numbered, opaque, and sealed envelopes. Investigators will remain blind to the sequence, with group assignments contained in envelopes marked only with case numbers. Before each case, a study nurse or assistant will open the corresponding numbered envelope to reveal the patient's group assignment.
- Dexmedetomidine (D):): Patients will receive a scalp block with a 20 ml syringe containing 1 mg/kg of 0.5% bupivacaine and 1 µg/kg of dexmedetomidine, with the remainder filled with saline.
- Ketamine (K): Patients will receive a scalp block with a 20 ml syringe containing 1 mg/kg of 0.5% bupivacaine and 2 mg/kg of ketamine, with the rest filled with saline. The syringes will be prepared by an anesthesia technician and handed blindly to the anesthetist to administer the block.
Study Protocol:
Patients visited the pre-anesthesia room before the procedure. All patients received explanation of Numerical Rating Scale (NRS) for pain assessment, which ranges from 0 (no pain) to 10 (most severe pain) [17].
Standard monitoring was applied, including electrocardiography (ECG), non-invasive, invasive blood pressure, and Oxygen Saturation (SaO₂), and baseline vital signs were recorded, including heart rate, systolic and diastolic blood pressure, mean arterial pressure, and oxygen saturation.
Anesthesia was induced with intravenous propofol 2 mg/kg, fentanyl 2 µg/kg, and atracurium 0.5 mg/kg, with mask ventilation for 3 minutes followed by tracheal intubation. Intraoperative signs of inadequate analgesia, such as tachycardia or hypertension exceeding 20% of baseline, were managed with additional 50 µg doses of fentanyl, and total fentanyl consumption was recorded. Anesthesia was maintained using intermittent positive pressure ventilation with isoflurane 0.8-1.2 MAC in an oxygen/air mixture, and atracurium infusion 0.5 mg/kg, while end-tidal CO₂ was monitored.
After induction, bilateral scalp blocks were performed using a 23G needle, with local anesthetic infiltrated around supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, lesser occipital, greater occipital, and great auricular nerves, 2-3 mL per nerve.
Scalp Block Techniques Supraorbital Nerve Block Patient was seated with the head slightly forward and eyes closed. The supraorbital notch was palpated, and a needle was inserted approximately 1 cm above the notch. 2 ml of local anesthetic were injected at this site.
Supratrochlear Nerve Block With the patient in the same position, the injection site was located one finger's breadth medial to the supraorbital nerve. The needle was redirected medially, and 3 mL of local anesthetic was administered.
Zygomaticotemporal Nerve Block The patient's head was turned so that the target side was facing upward. Landmarks included the orbital rim and zygomatic arch. A dual injection technique was used, with 1 mL injected deeply and 2 mL subcutaneously.
Auriculotemporal Nerve Block The injection site was 1-1.5 cm anterior to the ear, above the tragus, taking care to avoid superficial temporal artery. 3ml of local anesthetic were injected subcutaneously.
Greater Occipital Nerve Block With the head turned or the patient seated, the occipital artery was palpated, approximately 3-4 cm lateral to the external occipital protuberance. The needle was inserted perpendicular to the skin medial to the artery, and 3 mL of local anesthetic was injected subcutaneously.
Lesser Occipital Nerve Block Injection site was located about 2.5 cm lateral to the greater occipital nerve block site. 3 ml of local anesthetic were administered subcutaneously.
Great Auricular Nerve Block (Postauricular Branches) The injection site was 1.5 cm posterior to the ear at the level of the tragus. The needle was inserted perpendicular to the bone, withdrawn slightly, and 3 mL of local anesthetic was injected subcutaneously [5].
Hemodynamic Monitoring HR and BP were recorded baseline before induction, 1 and 5 minutes after induction, at intubation, 5 minutes after the scalp block, 5 minutes after pin insertion, 5minutes after skin incision, at 15min, 20min, 25min, 30min,35min, 40min,60min, 95min, 3hour, 4hour and after extubating as well as in post-anesthesia care unit (PACU) and upon arrival in surgical ICU.
Deviations from baseline were managed according to protocol:
- Bradycardia (<20% below baseline) was treated with atropine 0.04 mg/kg
- Hypotension (<20% below baseline) with ephedrine 5 mg IV
- Hypertension or tachycardia (>20% above baseline) with fentanyl 50 µg IV. At the end of surgery, residual neuromuscular blockade was reversed using atropine 0.01 mg/kg and neostigmine 0.05 mg/kg. Extubating was performed when the patient met standard criteria, including a Glasgow Coma Scale >8, adequate cough and gag reflex, sufficient motor strength, a train-of-four (TOF) ratio >0.9, ability to hold head tilt or hand grip for 5 seconds, adequate tidal volume and oxygenation and hemodynamic stability.
In PACU, standard monitoring was continued, pain was assessed using NRS. Patients were discharged when modified Aldrete Score exceeded 9 [18].
Paracetamol and ketorolac were given as rescue analgesia when NRS score was more than 4. The time from extubating to the first analgesic request was recorded, and total postoperative analgesic consumption was documented.
Any hemodynamic instability, including hypertension, tachycardia, bradycardia, or hypotension, as well as nausea, vomiting, and other complications, were recorded.
Hemodynamic monitoring (MAP in mmHg) was Pain assessment using NRS (0-10) was conducted upon PACU arrival, 2, 4, 6, 8, 12and 24 hours postop
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Dexmedetomidine (D) | Experimental | Drug: Scalp Block with BupivacainePatients will receive a scalp block with a 20 ml syringe containing 1 mg/kg of 0.5% bupivacaine and 1 µg/kg of dexmedetomidine, with the remainder filled with saline. |
| Ketamine (K): | Active comparator | Drug: Scalp Block with BupivacainePatients will receive a scalp block with a 20 ml syringe containing 1 mg/kg of 0.5% bupivacaine and 2 mg/kg of ketamine, with the rest filled with saline. The syringes will be prepared by an anesthesia technician and handed blindly to the anesthetist to administer the block. |
Who may qualify
- Ages
- 20 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Age from 20 to 60 years, both sexes, American Society of Anesthesiologists (ASA) physical status II-III, Supratentorial tumor excision, Supine Position.
- and operation time: less than 6 hours.
Key exclusion criteria (2 listed)
- Patient refusal, disturbed consciousness level (Glasgow Coma Scale [GCS] < 15). Patients who required reintubation during the study period, those not extubated. immediately after surgery, or those who awoke with neurological deficits impairing. pain assessments were excluded from the final analysis, history of psychotic disorders or previous surgeries, Poor cognitive function.
- Postictal state or uncontrolled/recurrent seizures, known allergy to dexmedetomidine or ketamine, difficult intubation (Mallampati score > III) or multiple intubation attempts, operation duration > 6 hours, renal dysfunction (creatinine > 1.2 mg/dL, BUN > 20 mg/dL), heart block and patients with chronic headache disorders or those receiving chronic analgesic therapy (for >3 months) were excluded.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Scalp Block with BupivacaineAfter induction, bilateral scalp blocks were performed using a 23G needle, with local anesthetic infiltrated around supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, lesser occipital, greater occipital, and great auricular nerves, 2-3 mL per nerve. | Drug | Dexmedetomidine (D), Ketamine (K): |
Primary outcome
Analgesic efficacy of dexmedetomidine versus ketamine as adjuvants in scalp blocks
Time frame: 6 hours
Compare analgesic efficacy of dexmedetomidine versus ketamine as adjuvants in scalp blocks for supratentorial tumor resection by measuring total intraoperative fentanyl consumption (in µg).
6 secondary outcomes
Compare the time duration after extubating to request the first analgesia.
Time frame: 24 hours
Total analgesic consumption.
Time frame: 24 hours
NRS pain score
Time frame: 24 hours
Nausea and vomiting
Time frame: 24 hours
Side effects
Time frame: 24 hours
Side effects
Time frame: 24 hours
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jul 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Regional Anesthesia Morbidity
Recruiting
Impact of Communication Delays on Anesthesia Response to Medical Emergencies and Ultrasound-Guided Regional Anesthesia
Regional Anesthesia, Regional Anesthesia Morbidity
Recruiting
Erector Spinae Block Versus Paravertebral Block on Chronic Pain After Mastectomy
Mastectomy; Lymphedema, Chronic Pain
Active, not recruitingObservational study
Retrospective Analysis of Pain After Nerve Block in Surgical Patients
Regional Anesthesia Morbidity, Acute Pain
Recruiting
Pericapsular Nerve Group (PENG) Block Combined With Lateral Femoral Cutaneous Nerve (LFCN) Block or Wound Infiltration for Postoperative Analgesia in Anterior Approach Total Hip Arthroplasty: A Randomized Controlled Trial
Arthropathy of Hip, Hip Arthropathy
Not yet recruitingObservational study
The Importance of Anesthesia Method in Fragile Patients
Frail Elderly Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Scalp Block with Bupivacaine in people with Regional Anesthesia Morbidity and Supratentorial Brain Tumor, run by Cairo University at 2 sites in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Analgesic efficacy of dexmedetomidine versus ketamine as adjuvants in scalp blocks (time frame: 6 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jul 2026.